Rilmenidine - Its antihypertensive efficacy, safety and impact on quality of life in perimenopausal women with mild to moderate essential hypertension

Blood Pressure

Volumn 15, Issue 1, 2006, Pages 51-58

  Kawecka Jaszcz, Kalina ^a   Czarnecka, Danuta ^a   Klocek, Marek ^a   Zabojszcz, Michał ^a   Kucharska, Marta ^b   Jaworski, Rafał ^b   Pachocki, Robert ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b Servier ^*  (Poland)

Author keywords

Hypertension; Menopause; Quality of life; Rilmenidine

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; RILMENIDINE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MONOTHERAPY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; SORE THROAT; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MIDDLE AGED; OXAZOLES; PERIMENOPAUSE; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 33644607786     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050600565969     Document Type: Article

References (20)

1. Safar, M. E. and Smulyan, H. (2004) Hypertension in women. Am J Hypertens, 17, pp. 82 - 87.
2. Ware, J. E. (1994) Hypertension - When is the clinical problem solved? When quality of life is secured. Cardiology, 85 Suppl 1, pp. 65 - 70.
3. Klocek, M. and Kawecka-Jaszcz, K. (2003) Quality of life in patients with essential arterial hypertension. Part I: The impact of sociodemographic factors. Przegl Lek, 60, pp. 92 - 100.
4. Klocek, M. and Kawecka-Jaszcz, K. (2003) Quality of life in patients with essential arterial hypertension. Part II: The impact of clinical factors. Przegl Lek, 60, pp. 101 - 106.
5. Roca-Cusachs, A. and Dalfo, A. and Badia, X. and Aristegui, I. and Roset, M. (2001) Relation between clinical and therapeutic variables and quality of life in hypertension. J. Hypertens, 19, pp. 1913 - 1919.
6. Wiklund, I. K.(1996) Hypertension. In Quality of life and clinical trials. (pp. 839 - 902). Philadelphia: Lippincott-Raven.
7. Bousquet, P. (2001) I1 receptors, cardiovascular function and metabolism. Am J Hypertens, 14, pp. 317 - 321.
8. De Luca, N. and Izzo, R. and Fonatana, D. and Iovino, G. and Argenziano, L. and Vecchione, C. and (2000) Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens, 18, pp. 1515 - 1522.
9. Esler, M. and Dudley, F. and Jennings, G. and Debinski, H. and Lambert, G. and Jones, P. and (1992) Increased sympathetic nervous system activity, and effects of its pharmacological inhibition, in alcoholic cirrhosis. Ann Intern Med, 116, pp. 446 - 455.
10. Anichkov, D. A. and Shostak, N. A. and Schastnaya, O. V. (2005) Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin, 21, pp. 113 - 119.
11. Manolis, A. J. and Olympios, C. and Sifaki, M. and Handanis, S. and Bresnahan, M. and Gavras, I. and (1995) Suppressing sympathetic activation in congestive heart failure: A new therapeutic strategy. Hypertension, 26, pp. 719 - 724.
12. Remkova, A. and Kratochvilova, H. (2002) Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension. J Hum Hypertens, 16, pp. 549 - 555.
13. Reid, J. (2001) Update on rilmenidine: Clinical benefits on sympathetic nervous system, I1 imidazoline receptors, hypertension and metabolic disorders. Am J Hypertens, 14, pp. 322S - 324S.
14. Fletcher, A. E. and Beevers, D. G. and Dollery, C. T. and Wilkinson, R. and Bulpitt, C. J. (1991) The effects of two centrally acting antihypertensive drugs on quality of life. Eur J Clin Pharmacol, 41, pp. 397 - 400.
15. Klocek, M. and Kawecka-Jaszcz, K. and Rynkiewicz, A. and Sobiczewski, W. (1999) Impact of rilmenidine on quality of life in patients with essential hypertension. Nadciśnienie Tetnicze, 1, pp. 27 - 34.
16. Tibirica, E. J. and Feldman, C. and Mermet, C. and Monassier, F. and Gonon, F. and Bousquet, P. (1991) Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors. Eur J Pharmacol, 209, pp. 213 - 221.
17. Dimenas, E. S. and Dalhof, C. and Olofsson, B. and Wiklund, I. K. (1990) An instrument for quantifying subjective symptoms among untreated and treated hypertensives: Development and documentation. J Clin Res Pharmacoepid, 4, pp. 205 - 217.
18. Degl'Innocenti, A. and Elmfeldt, D. and Hofman, A. and Lithell, H. and Olofsson, B. and Skoog, I. and (2004) Health-related quality of life during treatment of elderly patients with hypertension: Results from the Study on COgnition and Prognosis in the Elderly (SCOPE). J Hum Hypertens, 18, pp. 239 - 245.
19. Farsang, C. and Lengyel, M. and Borbas, S. and Zorandi, A. and Dienes, B. S. (2003) Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). Curr Med Res Opin, 19, pp. 205 - 217.
20. Esler, M. and Lux, A. and Jennings, G. and Hastings, J. and Socratous, F. and Lambert, G. (2004) Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. J Hypertens, 22, pp. 1529 - 1534.